Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; The University of Texas MD Anderson Cancer Center; Provention Bio, Inc.; and Molecular Partners AG. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone805-447-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$23.75 billion
Profitability
Miscellaneous
Employees21,500
Next Earnings Date4/23/2019 (Estimated)
OptionableOptionable
Amgen (NASDAQ:AMGN) Frequently Asked Questions
What is Amgen's stock symbol?
Amgen trades on the NASDAQ under the ticker symbol "AMGN."
How often does Amgen pay dividends? What is the dividend yield for Amgen?
Amgen announced a quarterly dividend on Friday, December 7th. Investors of record on Friday, February 15th will be paid a dividend of $1.45 per share on Friday, March 8th. This represents a $5.80 annualized dividend and a dividend yield of 3.11%. The ex-dividend date of this dividend is Thursday, February 14th. This is an increase from Amgen's previous quarterly dividend of $1.32. View Amgen's Dividend History.
How will Amgen's stock buyback program work?
Amgen declared that its board has approved a share buyback program on Friday, February 2nd 2018, which authorizes the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company's board believes its shares are undervalued.
How were Amgen's earnings last quarter?
Amgen, Inc. (NASDAQ:AMGN) released its quarterly earnings results on Tuesday, January, 29th. The medical research company reported $3.42 earnings per share for the quarter, topping analysts' consensus estimates of $3.26 by $0.16. The medical research company earned $6.23 billion during the quarter, compared to analyst estimates of $5.88 billion. Amgen had a net margin of 35.35% and a return on equity of 66.74%. During the same period in the previous year, the business posted $2.89 EPS. View Amgen's Earnings History.
When is Amgen's next earnings date?
What guidance has Amgen issued on next quarter's earnings?
Amgen updated its FY19 earnings guidance on Tuesday, January, 29th. The company provided earnings per share guidance of $13.10-14.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $14.66. The company issued revenue guidance of $21.8-22.9 billion, compared to the consensus revenue estimate of $22.92 billion.Amgen also updated its FY 2019 guidance to $13.10-14.30 EPS.
What price target have analysts set for AMGN?
16 brokerages have issued 12-month target prices for Amgen's shares. Their forecasts range from $179.00 to $232.00. On average, they anticipate Amgen's share price to reach $204.9375 in the next year. This suggests a possible upside of 9.8% from the stock's current price. View Analyst Price Targets for Amgen.
What is the consensus analysts' recommendation for Amgen?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 9 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amgen.
What are Wall Street analysts saying about Amgen stock?
Here are some recent quotes from research analysts about Amgen stock:
- 1. Mizuho analysts commented, "We also plan to unveil our buyside survey results in full detail and provide additional commentary on what we’re hearing from investors. This webinar will last 60 minutes. We will have slides (and I can’t promise a replay). Hope you can tune in. ===Ways to Access this Webinar=== 1. Link to add this webinar to your calendar ==> Click Here 2. Full-length URL (to use on day of webinar … click on it or cut/paste into your browser) ==> https://mizuhogroup.webex.com/mizuhogroup/onstage/ g.php?MTID=e55aa48dfcfbba81a9521ea1537d2ea77 3. Need audio-only cuz you’re travelling? ==> Email Me Please call / email with any questions – Salim PLEASE REFER TO PAGE 3 OF THIS REPORT FOR IMPORTANT DISCLOSURE AND ANALYST CERTIFICATION INFORMATION. Mizuho Securities USA LLC does and seeks to do business with companies covered in its research reports." (2/13/2019)
- 2. According to Zacks Investment Research, "Amgen’s newer drugs – Prolia, Xgeva, Blincyto, Kyprolis – are performing well. Amgen is also progressing with its pipeline and the approval of migraine candidate, Aimovig was a huge boost. Its strong biosimilars pipeline could be an important long-term growth driver. Amgen’s restructuring plan is making more cost efficient. Lower taxes and share buybacks should provide some bottom-line support. Amgen’s shares have outperformed the industry in the past year. However, Amgen faces challenges related to its more mature products such as launch of competing biosimilar versions of Neulasta and Epogen, further sales erosion of Neupogen and Aranesp and increasing competitive pressures on Enbrel. Meanwhile, uptake of key new drug, Repatha has been slow due to payer restrictions. Nonetheless, estimates have gone down slightly ahead of the Q4 earnings release. Amgen has a positive record of earnings surprises in recent quarters." (1/23/2019)
- 3. Cantor Fitzgerald analysts commented, "We visited Amgen’s headquarters in conjunction with our post ASH bus tour and met the company’s CFO, R&D head, and IR team. We highlight key takeaways in this note. Management continues to sound very bullish about the Aimovig launch even as competitors launch. We could expect a decision on the Sandoz case around the mediation in Jan. We would expect 2019 guidance range to be as wide or a bit wider than 2018 due to biosimilars. From speaking to management, we think the biggest moving piece is Neulasta experiencing now two biosimilar competitors. When looking at analogs, the company notes drug lost about 50% share, but Amgen has the OnPro device, which may allow it to slow the rate of branded loss. Sensipar ($1.7B ’18 Bloomberg consensus) is a moving piece since generics have not launched at risk." (12/4/2018)
Has Amgen been receiving favorable news coverage?
Media stories about AMGN stock have been trending somewhat positive recently, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Amgen earned a daily sentiment score of 1.7 on InfoTrie's scale. They also assigned news headlines about the medical research company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are some of Amgen's key competitors?
Some companies that are related to Amgen include Gilead Sciences (GILD), Biogen (BIIB), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), BIO-TECHNE (TECH), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), argenx (ARGX), Ablynx (ABLYF), Allogene Therapeutics (ALLO), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO) and Denali Therapeutics (DNLI).
What other stocks do shareholders of Amgen own?
Who are Amgen's key executives?
Amgen's management team includes the folowing people:
- Mr. Robert A. Bradway, Chairman & CEO (Age 56)
- Mr. David W. Meline, Exec. VP & CFO (Age 62)
- Mr. Jonathan P. Graham, Sr. VP, Gen. Counsel & Sec. (Age 58)
- Mr. Esteban Santos, Exec. VP of Operations (Age 51)
- Mr. Mike Zahigian, Sr. VP & Chief Information Officer
Who are Amgen's major shareholders?
Amgen's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.24%), Oregon Public Employees Retirement Fund (4.93%), Northern Trust Corp (1.44%), Geode Capital Management LLC (1.39%), Bank of New York Mellon Corp (1.07%) and Nordea Investment Management AB (0.72%). Company insiders that own Amgen stock include Carbonnel Francois De, Cynthia M Patton, Ronald D Sugar, Sean E Harper and Tyler Jacks. View Institutional Ownership Trends for Amgen.
Which major investors are selling Amgen stock?
AMGN stock was sold by a variety of institutional investors in the last quarter, including Polar Capital LLP, Pzena Investment Management LLC, Bank of New York Mellon Corp, Connor Clark & Lunn Investment Management Ltd., Assenagon Asset Management S.A., HM Payson & Co., Rhumbline Advisers and Van ECK Associates Corp. Company insiders that have sold Amgen company stock in the last year include Cynthia M Patton, Ronald D Sugar, Sean E Harper and Tyler Jacks. View Insider Buying and Selling for Amgen.
Which major investors are buying Amgen stock?
AMGN stock was acquired by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, BlackRock Inc., Geode Capital Management LLC, Epoch Investment Partners Inc., Northern Trust Corp, Bahl & Gaynor Inc., Two Sigma Advisers LP and Mackay Shields LLC. View Insider Buying and Selling for Amgen.
How do I buy shares of Amgen?
Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amgen's stock price today?
One share of AMGN stock can currently be purchased for approximately $186.70.
How big of a company is Amgen?
Amgen has a market capitalization of $116.18 billion and generates $23.75 billion in revenue each year. The medical research company earns $8.39 billion in net income (profit) each year or $14.40 on an earnings per share basis. Amgen employs 21,500 workers across the globe.
What is Amgen's official website?
How can I contact Amgen?
Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]
MarketBeat Community Rating for Amgen (NASDAQ AMGN)
MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe AMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
